Hennion & Walsh Asset Management Inc. Sells 17,560 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 15.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,294 shares of the company’s stock after selling 17,560 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Mirum Pharmaceuticals were worth $7,764,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $1,478,000. NorthCrest Asset Manangement LLC bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $406,000. Tudor Investment Corp ET AL purchased a new position in Mirum Pharmaceuticals during the 3rd quarter valued at $2,027,000. CIBC Bancorp USA Inc. bought a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $315,000. Finally, PharVision Advisers LLC bought a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $273,000.

Analysts Set New Price Targets

A number of analysts have weighed in on MIRM shares. Evercore set a $126.00 target price on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. TD Cowen upped their price target on shares of Mirum Pharmaceuticals from $117.00 to $125.00 and gave the stock a “buy” rating in a report on Friday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Royal Bank Of Canada decreased their price objective on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $117.67.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $88.44 on Monday. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $109.28. The firm has a market cap of $5.34 billion, a PE ratio of -184.25 and a beta of 0.52. The business has a fifty day simple moving average of $96.36 and a two-hundred day simple moving average of $81.80. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The firm had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.Mirum Pharmaceuticals’s quarterly revenue was up 49.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.00 EPS. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 16,515 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the transaction, the chief operating officer owned 40,272 shares of the company’s stock, valued at approximately $3,704,218.56. This trade represents a 29.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Eric Bjerkholt sold 7,287 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the chief financial officer owned 49,788 shares of the company’s stock, valued at approximately $4,579,500.24. This represents a 12.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 121,942 shares of company stock valued at $11,416,645 over the last quarter. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.